Influence of HER2 expression on prognosis in metastatic triple-negative breast cancerdresults from an international, multicenter analysis coordinated by the AGMT Study Group

Gampenrieder, S. P.; Dezentje, V.; Lambertini, M.; de Nonneville, A.; Marhold, M.; Le Du, F.; Salgado, A. Cortes; Costa, D. Alpuim; Batista, M. Vaz; Ruche, N. Chic; Tinchon, C.; Petzer, A.; Blondeaux, E.; Del Mastro, L.; Targato, G.; Bertucci, F.; Goncalves, A.; Viret, F.; Bartsch, R.; Mannsbart, C.; Deleuze, A.; Robert, L.; Serrano, C. Saavedra; Cortes, M. Gion; Sampaio-Alves, M.; Vitorino, M.; Pecen, L.; Singer, C.; Harbeck, N.; Rinnerthaler, G. und Greil, R. (2022): Influence of HER2 expression on prognosis in metastatic triple-negative breast cancerdresults from an international, multicenter analysis coordinated by the AGMT Study Group. In: ESMO Open, Bd. 8, Nr. 1, 100747

Abstract

Background: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC.Patients and methods: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ER882 gene amplification. Survival probabilities were calculated by the KaplaneMeier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models.Results: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265;29.8%) and primary tumors (n = 425;33.4%;P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00;95% CI 0.83-1.19;P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95;95% CI 0.79-1.13;P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89;95% CI 0.69-1.17;P = 0.414). Conclusions: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable HER2-low showed influence on OS.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch